EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI-Driven Biomarkers

Cristina Quicios Dorado, Ana Sánchez Ramírez, Marta Pérez Pérez, Manuel Saavedra Centeno, Lira Pelari Mici iD, Carlos Márquez Güemez, Eduardo Albers Acosta iD, Guillermo Celada Luis, Martin Costal, Patricia Toquero Diez, Nuria Romero Laorden, Raquel Jover Díaz und 2 weitere

Cancers · 24.11.2025 · 17 (23) · 3747

DOI: 10.3390/cancers17233747 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.11.2025. Verfasst von Cristina Quicios Dorado und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Prostate cancer is the most prevalent malignancy in men and remains a leading cause of cancer-related mortality worldwide. Conventional imaging modalities exhibit limited sensitivity, particularly in the context of disease recurrence and advanced disease.

Methods

A narrative review was conducted of studies published between 2015 and 2025, identified through PubMed, Embase, and Cochrane. Eligible publications addressed advanced imaging techniques, PSMA-targeted diagnostics and therapies, radiogenomics, liquid biopsy approaches, and artificial intelligence applications and personalized medicine. Preclinical studies, single case reports, and conference abstracts without full text were excluded.

Results

PSMA PET/CT outperforms conventional imaging for detection, and restaging, influencing clinical management across disease stages. Lutetium-177–PSMA-617 has become the standard radioligand therapy for metastatic castration-resistant prostate cancer, whereas alpha-emitting agents remain under clinical investigation. Radiogenomics and liquid biopsy assays (ctDNA, CTCs, AR-V7) provide complementary molecular insights. Artificial intelligence enhances imaging interpretations, standardization, and reproducibility, while multimodal data integration supports individualized risk stratification. Integrative models combining imaging, genomic, and liquid biopsy data pave the way toward precision oncology and personalized therapeutic decision-making.

Conclusions

Advances in imaging and theragnostics are reshaping prostate cancer management, bridging the gap between molecular biology and clinical practice to enable precision oncology.

Schlagwörter

Stichwörter der Autor:innen

PET/CTPET/MRIPSMAartificial intelligencecirculating tumor cellsctDNAintegrative modelsliquid biopsypersonalized medicineprostate cancerradiogenomicsradioligand therapyradiomicstheragnostics

Autor:innen und Institutionen

  • Department of Urology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain.
  • Department of Urology, Hospital Universitario del Henares, 28822 Madrid, Spain.
  • Department of Medical Oncology, Hospital Universitario de La Princesa, IIS Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain.
  • Department of Nuclear Medicine, Hospital Universitario de La Princesa, IIS Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain.

ORCID-Profile: Lira Pelari Mici, Eduardo Albers Acosta, Clara Velasco Balanza, Luis San José Manso

Zitieren

APA

Dorado, C. Q., Ramírez, A. S., Pérez, M. P., Centeno, M. S., Mici, L. P., Güemez, C. M., Albers Acosta, E., Luis, G. C., Costal, M., Diez, P. T., Laorden, N. R., Díaz, R. J., Velasco Balanza, C., & Manso, L. S. J. (2025). Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI-Driven Biomarkers. Cancers, 17(23), 3747. https://doi.org/10.3390/cancers17233747

Vancouver

Dorado CQ, Ramírez AS, Pérez MP, Centeno MS, Mici LP, Güemez CM, et al. Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI-Driven Biomarkers. Cancers. 2025;17(23):3747. doi:10.3390/cancers17233747

BibTeX
@article{Dorado2025,
  author = {Dorado, Cristina Quicios and Ramírez, Ana Sánchez and Pérez, Marta Pérez and Centeno, Manuel Saavedra and Mici, Lira Pelari and Güemez, Carlos Márquez and Albers Acosta, Eduardo and Luis, Guillermo Celada and Costal, Martin and Diez, Patricia Toquero and Laorden, Nuria Romero and Díaz, Raquel Jover and Velasco Balanza, Clara and Manso, Luis San José},
  title = {Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI-Driven Biomarkers},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {23},
  pages = {3747},
  doi = {10.3390/cancers17233747}
}
Kostenlos starten →